All Press Releases
Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase
Malmö, October 11, 2022 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety study in rats has completed the in-life phase with no adverse signals during the dosing phase. Outstanding investigations still to be completed include the pathology, and the bioanalysis and toxicokinetic analyses which are necessary to determine the…
Pila Pharma delårsrapport för 1 april – 30 juni 2022
Malmö, 26 augusti 2022 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets delårsrapport för perioden april – juni 2022 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information SAMMANFATTNING AV DELÅRSRAPPORT Andra kvartalet (1 april–30 juni 2022) Rörelsens intäkter uppgick till 651 kSEK (0)Rörelseresultatet (EBIT) uppgick till - 2 250 kSEK (-…
Pila Pharma publishes interim report April 1 – June 30, 2022
Malmö, August 26, 2022 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period April – June 2022. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information SUMMARY OF YEAR-END REPORT Second quarter (April 1 – June 30, 2022) Revenue was SEK 651 kSEK (0)Operating loss (EBIT) was…